公开(公告)号：KR1020070036450A

公开(公告)日：2007-04-03

申请号：KR1020050091476

申请日：2005-09-29

Applicant: 전북대학교산학협력단

Inventor： 박성광 ,  김원 ,  이식 ,  문상옥

IPC: A61K31/385 ,  A61K31/095

CPC classification number: A61K31/385

Abstract: The present invention relates to a pharmaceutical composition containing alpha-lipoic acid (LA) as an active ingredient. alpha-lipoic acid is an inhibitor of fractalkine expression, and exhibits effects of alleviating inflammation due to endotoxemia by decreasing expression of fractalkine and attachment of endothelial cells to monocytes in endothelial cells of an LPS-induced endotoxemia model.

公开(公告)号：KR1020070006497A

公开(公告)日：2007-01-11

申请号：KR1020050061884

申请日：2005-07-08

Applicant: 전북대학교산학협력단

Inventor： 박성광 ,  김원 ,  이식 ,  문상옥

IPC: A61K31/4523 ,  A61K31/454 ,  A61K31/4535

CPC classification number: A61K31/4439 ,  A61K9/0012 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/10 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/426

Abstract: A pharmaceutical composition comprising rosiglitazone is provided to be useful for decreasing renal disorders caused by sepsis, thereby being applied as a material useful for developing therapeutic agents effective for decreasing death rate and symptoms of a disease. The pharmaceutical composition for inhibiting renal disorders comprises rosiglitazone represented by the formula(1), a salt thereof or a derivative thereof. In the formula(1), each A and A' is independently Co N, R1 is C1-5 alkyl or H, and R2 is C1-5 alkyl, H, or hydroxy.

Abstract translation: 提供包含罗格列酮的药物组合物可用于减少由败血症引起的肾脏疾病，从而作为可用于开发有效降低死亡率和疾病症状的治疗剂的材料。 用于抑制肾脏疾病的药物组合物包括由式（1）表示的罗格列酮，其盐或其衍生物。 在式（1）中，A和A'各自独立地是Co N，R 1是C 1-5烷基或H，R 2是C 1-5烷基，H或羟基。

公开(公告)号：KR1020070032156A

公开(公告)日：2007-03-21

申请号：KR1020050087096

申请日：2005-09-16

Applicant: 전북대학교산학협력단

Inventor： 박성광 ,  김원 ,  이식 ,  문상옥

IPC: A61K31/05

Abstract: 본 발명은 레스베라트롤을 유효성분으로 함유하는 약제학적 조성물에 관한 것으로, 레스베라트롤은 프랙트알킨 발현의 저해제로서, TNF-α의 유도로 인한 염증 모델의 동맥 상피세포에서 프랙트알킨의 발현과 단핵세포에 대한 내피세포의 부착을 감소시키므로 염증을 경감시키는 효과를 갖는다.
레스베라트롤, 프랙트알킨, 내피세포, 염증